In addition, to validate the in silico results against triple-negative breast cancer (TNBC) MDA-MB-231, an in vitro vascular endothelial growth factor receptor-2 (VEGFR-2) inhibition assay was conducted. This evidence concerns the gene KDR and triple-negative breast carcinoma.